Louise Kuhn1,2, Maria Paximadis3, Bianca Da Costa Dias3, Yanhan Shen1, Sizanani Mncube3, Renate Strehlau4, Stephanie Shiau5, Faeezah Patel4,6, Megan Burke4, Karl-Günter Technau4, Gayle Sherman3,4, Shayne Loubser3, Elaine J Abrams7,8, Caroline T Tiemessen3. 1. Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA. 2. Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, USA. 3. Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services, and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 4. Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 5. Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey, USA. 6. Wits Reproductive Health and HIV Institute (WRHI), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 7. ICAP at Columbia University, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, USA. 8. Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA.
Abstract
BACKGROUND: Younger age of antiretroviral therapy (ART) initiation is associated with smaller viral reservoirs in perinatally acquired HIV-1 infection, but there is wide variability among early-treated infants. Predictors of this variability are not fully described. METHODS: Sixty-three neonates diagnosed with HIV-1 <48 hours after birth in Johannesburg, South Africa, were started on ART as soon as possible. Fifty-nine (94%) infants received nevirapine prophylaxis from birth until ART start. Viably preserved peripheral blood mononuclear cells (PBMCs) collected at regular intervals to 48 weeks, and from mothers at enrollment, were tested using integrase-targeted, semi-nested, real-time quantitative hydrolysis probe (TaqMan) PCR assays to quantify total HIV-1 subtype C viral DNA (vDNA). Predictors were investigated using generalized estimating equation regression. RESULTS: Thirty-one (49.2%) infants initiated ART <48 hours, 24 (38.1%) <14 days, and 8 (12.7%) >14 days of birth. Three-quarters were infected despite maternal antenatal ART (however, only 9.5% of women had undetectable viral load closest to delivery) and 86% were breastfed. Higher infant CD4+ T-cell percentage and viral load <100 000 copies/mL pre-ART were associated with lower vDNA in the first 48 weeks after ART start. No antenatal maternal ART and breastfeeding were also associated with lower vDNA. Older age at ART initiation had a discernible negative impact when initiated >14 days. CONCLUSIONS: Among very early treated infants, higher CD4+ T-cell percentage and viral load <100 000 copies/mL pre-ART, infection occurring in the absence of maternal antenatal ART, and breastfeeding were associated with lower levels of HIV-1 DNA in the first 48 weeks of treatment. Clinical Trials Registration. clinicaltrials.gov (NCT02431975).
BACKGROUND: Younger age of antiretroviral therapy (ART) initiation is associated with smaller viral reservoirs in perinatally acquired HIV-1 infection, but there is wide variability among early-treated infants. Predictors of this variability are not fully described. METHODS: Sixty-three neonates diagnosed with HIV-1 <48 hours after birth in Johannesburg, South Africa, were started on ART as soon as possible. Fifty-nine (94%) infants received nevirapine prophylaxis from birth until ART start. Viably preserved peripheral blood mononuclear cells (PBMCs) collected at regular intervals to 48 weeks, and from mothers at enrollment, were tested using integrase-targeted, semi-nested, real-time quantitative hydrolysis probe (TaqMan) PCR assays to quantify total HIV-1 subtype C viral DNA (vDNA). Predictors were investigated using generalized estimating equation regression. RESULTS: Thirty-one (49.2%) infants initiated ART <48 hours, 24 (38.1%) <14 days, and 8 (12.7%) >14 days of birth. Three-quarters were infected despite maternal antenatal ART (however, only 9.5% of women had undetectable viral load closest to delivery) and 86% were breastfed. Higher infant CD4+ T-cell percentage and viral load <100 000 copies/mL pre-ART were associated with lower vDNA in the first 48 weeks after ART start. No antenatal maternal ART and breastfeeding were also associated with lower vDNA. Older age at ART initiation had a discernible negative impact when initiated >14 days. CONCLUSIONS: Among very early treated infants, higher CD4+ T-cell percentage and viral load <100 000 copies/mL pre-ART, infection occurring in the absence of maternal antenatal ART, and breastfeeding were associated with lower levels of HIV-1 DNA in the first 48 weeks of treatment. Clinical Trials Registration. clinicaltrials.gov (NCT02431975).
Authors: Katherine Luzuriaga; Barbara Tabak; Manuel Garber; Ya Hui Chen; Carrie Ziemniak; Margaret M McManus; Danielle Murray; Matthew C Strain; Douglas D Richman; Tae-Wook Chun; Coleen K Cunningham; Deborah Persaud Journal: J Infect Dis Date: 2014-05-21 Impact factor: 5.226
Authors: Alfredo Tagarro; Man Chan; Paola Zangari; Bridget Ferns; Caroline Foster; Anita De Rossi; Eleni Nastouli; María A Muñoz-Fernández; Diana Gibb; Paolo Rossi; Carlo Giaquinto; Abdel Babiker; Claudia Fortuny; Riccardo Freguja; Nicola Cotugno; Ali Judd; Antoni Noguera-Julian; María Luisa Navarro; María José Mellado; Nigel Klein; Paolo Palma; Pablo Rojo Journal: J Acquir Immune Defic Syndr Date: 2018-10-01 Impact factor: 3.731
Authors: Pilar Garcia-Broncano; Shivaali Maddali; Kevin B Einkauf; Chenyang Jiang; Ce Gao; Joshua Chevalier; Fatema Z Chowdhury; Kenneth Maswabi; Gbolahan Ajibola; Sikhulile Moyo; Terence Mohammed; Thabani Ncube; Joseph Makhema; Patrick Jean-Philippe; Xu G Yu; Kathleen M Powis; Shahin Lockman; Daniel R Kuritzkes; Roger Shapiro; Mathias Lichterfeld Journal: Sci Transl Med Date: 2019-11-27 Impact factor: 17.956
Authors: Kirsten A Veldsman; Anita Janse van Rensburg; Shahieda Isaacs; Shalena Naidoo; Barbara Laughton; Carl Lombard; Mark F Cotton; John W Mellors; Gert U van Zyl Journal: J Int AIDS Soc Date: 2019-08 Impact factor: 5.396
Authors: Ciputra Adijaya Hartana; Pilar Garcia-Broncano; Yelizaveta Rassadkina; Xiaodong Lian; Chenyang Jiang; Kevin B Einkauf; Kenneth Maswabi; Gbolahan Ajibola; Sikhulile Moyo; Terence Mohammed; Comfort Maphorisa; Joseph Makhema; Yuko Yuki; Maureen Martin; Kara Bennett; Patrick Jean-Philippe; Mathias Viard; Michael D Hughes; Kathleen M Powis; Mary Carrington; Shahin Lockman; Ce Gao; Xu G Yu; Daniel R Kuritzkes; Roger Shapiro; Mathias Lichterfeld Journal: Cell Rep Date: 2022-07-19 Impact factor: 9.995